Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,664,703
  • Shares Outstanding, K 143,881
  • Annual Sales, $ 118,190 K
  • Annual Income, $ -121,000 K
  • 60-Month Beta 1.74
  • Price/Sales 13.80
  • Price/Cash Flow N/A
  • Price/Book 3.51
Trade SGMO with:

Options Overview

Details
  • Implied Volatility 52.06%
  • Historical Volatility 31.81%
  • IV Percentile 2%
  • IV Rank 6.09%
  • IV High 156.15% on 12/10/20
  • IV Low 45.31% on 06/15/21
  • Put/Call Vol Ratio 0.59
  • Today's Volume 1,060
  • Volume Avg (30-Day) 865
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 40,461
  • Open Int (30-Day) 39,041

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.31
  • Number of Estimates 8
  • High Estimate -0.19
  • Low Estimate -0.35
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -19.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.42 +7.97%
on 05/25/21
11.93 -5.70%
on 06/09/21
+0.43 (+3.97%)
since 05/21/21
3-Month
9.76 +15.27%
on 05/11/21
13.50 -16.67%
on 03/23/21
-2.34 (-17.22%)
since 03/22/21
52-Week
8.51 +32.20%
on 06/29/20
19.43 -42.10%
on 12/28/20
+2.09 (+22.82%)
since 06/22/20

Most Recent Stories

More News
Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal

Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.

BIIB : 375.61 (-1.39%)
SGMO : 11.23 (-2.94%)
SAGE : 55.98 (-2.54%)
DNLI : 70.16 (-3.53%)
BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review

The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.

RHHBY : 46.8900 (-1.24%)
PFE : 39.62 (+0.51%)
BMRN : 80.83 (+0.09%)
SGMO : 11.23 (-2.94%)
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective...

SGMO : 11.23 (-2.94%)
Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4th at...

SGMO : 11.23 (-2.94%)
Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study

Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.

BIIB : 375.61 (-1.39%)
SGMO : 11.23 (-2.94%)
SAGE : 55.98 (-2.54%)
DNLI : 70.16 (-3.53%)
Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate

Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)

BIIB : 375.61 (-1.39%)
SGMO : 11.23 (-2.94%)
SAGE : 55.98 (-2.54%)
DNLI : 70.16 (-3.53%)
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders

Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.

BIIB : 375.61 (-1.39%)
SGMO : 11.23 (-2.94%)
SAGE : 55.98 (-2.54%)
DNLI : 70.16 (-3.53%)
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -10.34% and -17.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

SGMO : 11.23 (-2.94%)
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results.

SGMO : 11.23 (-2.94%)
Sangamo Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 4, 2021 / Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 5:00...

SGMO : 11.23 (-2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 11.98
2nd Resistance Point 11.78
1st Resistance Point 11.67
Last Price 11.23
1st Support Level 11.36
2nd Support Level 11.16
3rd Support Level 11.05

See More

52-Week High 19.43
Fibonacci 61.8% 15.26
Fibonacci 50% 13.97
Fibonacci 38.2% 12.68
Last Price 11.23
52-Week Low 8.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar